title: Dronedarone for atrial fibrillation: How does it compare with amiodarone?
abstract: Dronedarone (Multaq), an analogue of amiodarone (Cordarone), was designed to cause fewer adverse effects than the parent compound. Studies have indeed shown dronedarone to be safer than amiodarone, but less effective. Its official indication is to reduce the risk of hospitalization in patients with paroxysmal or persistent atrial fibrillation or atrial flutter and other cardiovascular risk factors, reflecting the parameters of its effectiveness in clinical trials.
authors.affiliation: Department of Internal Medicine, Lankenau Hospital, Wynnewood, PA 19096, USA. pneelu@gmail.com
authors.forename: Neelima
authors.initials: N
authors.lastname: Penugonda
authors.forename: Adam
authors.initials: A
authors.lastname: Mohmand-Borkowski
authors.forename: James F
authors.initials: JF
authors.lastname: Burke
mesh_terms: D000638:Amiodarone / Q000031:analogs & derivatives* / Q000191:economics / Q000494:pharmacology / Q000627:therapeutic use*; D000889:Anti-Arrhythmia Agents / Q000627:therapeutic use*; D001281:Atrial Fibrillation / Q000188:drug therapy*; D000077764:Dronedarone; D004347:Drug Interactions; D006801:Humans; D011306:Prescription Fees
chemical_list: D000889:Anti-Arrhythmia Agents; D000077764:Dronedarone; D000638:Amiodarone